{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T21:13:14Z","timestamp":1770412394648,"version":"3.49.0"},"reference-count":28,"publisher":"American Society of Hematology","issue":"9","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2013,2,28]]},"abstract":"<jats:title>Key Points<\/jats:title>\n               <jats:p>Thalidomide and prednisone maintenance after transplantation improves progression-free but not overall survival.<\/jats:p>","DOI":"10.1182\/blood-2012-09-451872","type":"journal-article","created":{"date-parts":[[2013,1,8]],"date-time":"2013-01-08T12:39:36Z","timestamp":1357648776000},"page":"1517-1523","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":124,"title":["A randomized phase 3 trial of thalidomide and prednisone as maintenance therapy after ASCT in patients with MM with a quality-of-life assessment: the National Cancer Institute of Canada Clinicals Trials Group Myeloma 10 Trial"],"prefix":"10.1182","volume":"121","author":[{"given":"A. Keith","family":"Stewart","sequence":"first","affiliation":[{"name":"Mayo Clinic, Scottsdale, AZ;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suzanne","family":"Trudel","sequence":"additional","affiliation":[{"name":"Princess Margaret Hospital, Toronto, ON;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nizar J.","family":"Bahlis","sequence":"additional","affiliation":[{"name":"Tom Baker Cancer Centre, Calgary, AB;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Darrell","family":"White","sequence":"additional","affiliation":[{"name":"QEII Health Sciences Center, Halifax, NS;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Waleed","family":"Sabry","sequence":"additional","affiliation":[{"name":"Saskatoon Cancer Centre, Saskatoon, SK;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Belch","sequence":"additional","affiliation":[{"name":"Cross Cancer Institute, Edmonton, AB;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tony","family":"Reiman","sequence":"additional","affiliation":[{"name":"Saint John Regional Cancer Centre, St John, NB;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean","family":"Roy","sequence":"additional","affiliation":[{"name":"Maisonneuve-Rosemont Hospital, Montreal, QC;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chaim","family":"Shustik","sequence":"additional","affiliation":[{"name":"McGill University, Montreal, QC;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael J.","family":"Kovacs","sequence":"additional","affiliation":[{"name":"London Health Sciences Centre, London, ON;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Morel","family":"Rubinger","sequence":"additional","affiliation":[{"name":"Cancer Care Manitoba, Winnipeg, MB;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guy","family":"Cantin","sequence":"additional","affiliation":[{"name":"Centre Hospitalier Affili\u00e9 Hopital Enfant-Jesus, Quebec City, QC;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin","family":"Song","sequence":"additional","affiliation":[{"name":"British Columbia Cancer Agency Vancouver, Vancouver, BC;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kirsty A.","family":"Tompkins","sequence":"additional","affiliation":[{"name":"Dr H. Bliss Murphy Cancer Centre, St John's, NL;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deb C.","family":"Marcellus","sequence":"additional","affiliation":[{"name":"Juravinski Cancer Centre, Hamilton, ON;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martha Q.","family":"Lacy","sequence":"additional","affiliation":[{"name":"Mayo Clinic, Rochester, MN;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Sussman","sequence":"additional","affiliation":[{"name":"Juravinski Cancer Centre, Hamilton, ON;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donna","family":"Reece","sequence":"additional","affiliation":[{"name":"Princess Margaret Hospital, Toronto, ON;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Brundage","sequence":"additional","affiliation":[{"name":"Cancer Centre of Southeastern Ontario, Kingston ON; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erica L.","family":"Harnett","sequence":"additional","affiliation":[{"name":"National Cancer Institute of Canada Clinical Trials Group, Kingston, ON"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lois","family":"Shepherd","sequence":"additional","affiliation":[{"name":"National Cancer Institute of Canada Clinical Trials Group, Kingston, ON"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judy-Anne W.","family":"Chapman","sequence":"additional","affiliation":[{"name":"National Cancer Institute of Canada Clinical Trials Group, Kingston, ON"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ralph M.","family":"Meyer","sequence":"additional","affiliation":[{"name":"National Cancer Institute of Canada Clinical Trials Group, Kingston, ON"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"issue":"5","key":"2019111907535828700_B1","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1182\/blood-2007-08-104984","article-title":"Recent major improvement in long-term survival of younger patients with multiple myeloma.","volume":"111","author":"Brenner","year":"2008","journal-title":"Blood"},{"issue":"2","key":"2019111907535828700_B2","doi-asserted-by":"crossref","first-page":"270","DOI":"10.3324\/haematol.13782","article-title":"Expected long-term survival of patients diagnosed with multiple myeloma in 2006-2010.","volume":"94","author":"Brenner","year":"2009","journal-title":"Haematologica"},{"issue":"14","key":"2019111907535828700_B3","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1200\/JCO.2010.32.5878","article-title":"Current trends in autologous stem-cell transplantation for myeloma in the era of novel therapies.","volume":"29","author":"Moreau","year":"2011","journal-title":"J Clin Oncol"},{"issue":"10","key":"2019111907535828700_B4","doi-asserted-by":"crossref","first-page":"3289","DOI":"10.1182\/blood-2006-05-022962","article-title":"Maintenance therapy with thalidomide improves survival in patients with multiple myeloma.","volume":"108","author":"Attal","year":"2006","journal-title":"Blood"},{"issue":"11","key":"2019111907535828700_B5","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1200\/JCO.2008.18.8573","article-title":"Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure.","volume":"27","author":"Spencer","year":"2009","journal-title":"J Clin Oncol"},{"issue":"6","key":"2019111907535828700_B6","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1182\/blood-2009-05-222539","article-title":"A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma.","volume":"115","author":"Lokhorst","year":"2010","journal-title":"Blood"},{"issue":"8","key":"2019111907535828700_B7","doi-asserted-by":"crossref","first-page":"3115","DOI":"10.1182\/blood-2008-03-145235","article-title":"Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities.","volume":"112","author":"Barlogie","year":"2008","journal-title":"Blood"},{"issue":"1","key":"2019111907535828700_B8","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2011-06-357038","article-title":"The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis.","volume":"119","author":"Morgan","year":"2012","journal-title":"Blood"},{"issue":"24","key":"2019111907535828700_B9","doi-asserted-by":"crossref","first-page":"8170","DOI":"10.1158\/1078-0432.CCR-04-1106","article-title":"Results of a multicenter randomized phase II trial of thalidomide and prednisone maintenance therapy for multiple myeloma after autologous stem cell transplant.","volume":"10","author":"Stewart","year":"2004","journal-title":"Clin Cancer Res"},{"key":"2019111907535828700_B10","unstructured":"National Cancer Institute Cancer Therapy Evaluation Program\n          National Cancer Institute Common Toxicity Criteria (v2.0).\n          1999\n          Accessed July 2, 2012\n          Bethesda, MD\n          National Institutes of Health\n          \n            http:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.html"},{"issue":"5","key":"2019111907535828700_B11","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1046\/j.1365-2141.1998.00930.x","article-title":"Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation.","volume":"102","author":"Blade","year":"1998","journal-title":"Br J Haematol"},{"issue":"5","key":"2019111907535828700_B12","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology.","volume":"85","author":"Aaronson","year":"1993","journal-title":"J Natl Cancer Inst"},{"issue":"282","key":"2019111907535828700_B13","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric Estimation from Incomplete Observations.","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"key":"2019111907535828700_B14","first-page":"719","article-title":"Statistical aspects of the analysis of data from retrospective studies of disease.","volume":"22","author":"Mantel","year":"1959","journal-title":"J Natl Cancer Inst"},{"issue":"1\/2","key":"2019111907535828700_B15","doi-asserted-by":"crossref","first-page":"203","DOI":"10.2307\/2333825","article-title":"A Generalized Wilcoxon Test for Comparing Arbitrarily Singly-Censored Samples.","volume":"52","author":"Gehan","year":"1965","journal-title":"Biometrika"},{"issue":"3","key":"2019111907535828700_B16","doi-asserted-by":"crossref","first-page":"659","DOI":"10.2307\/2336502","article-title":"Discrete sequential boundaries for clinical trials.","volume":"70","author":"Lan","year":"1983","journal-title":"Biometrika"},{"key":"2019111907535828700_B17","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2307\/2342435","article-title":"The logic of inductive inference.","volume":"98","author":"Fisher","year":"1935","journal-title":"J Royal Stat Soc"},{"issue":"2","key":"2019111907535828700_B18","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1586\/erp.10.15","article-title":"Added value of health-related quality of life measurement in cancer clinical trials: the experience of the NCIC-CTG.","volume":"10","author":"Au","year":"2010","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"4","key":"2019111907535828700_B19","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/j.1600-0609.2009.01303.x","article-title":"Health-related quality of life assessment in randomised controlled trials in multiple myeloma: a critical review of methodology and impact on treatment recommendations.","volume":"83","author":"Kvam","year":"2009","journal-title":"Eur J Haematol"},{"issue":"6","key":"2019111907535828700_B20","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1182\/blood-2002-03-0889","article-title":"Overall and event-free survival are not improved by the use of myeloablative therapy following intensified chemotherapy in previously untreated patients with multiple myeloma: a prospective randomized phase 3 study.","volume":"101","author":"Segeren","year":"2003","journal-title":"Blood"},{"issue":"2","key":"2019111907535828700_B21","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1046\/j.1365-2141.1996.d01-1802.x","article-title":"Effect of interferon on the health-related quality of life of multiple myeloma patients: results of a Nordic randomized trial comparing melphalan and prednisone to melphalan, prednisone-and alpha interferon.","volume":"94","author":"Wisloff","year":"1996","journal-title":"Br J Haematol"},{"issue":"3","key":"2019111907535828700_B22","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/j.1365-2141.1995.tb08364.x","article-title":"Interferon alfa-2b versus no maintenance therapy during the plateau phase in multiple myeloma: a randomized study.","volume":"89","author":"Westin","year":"1995","journal-title":"Br J Haematol"},{"issue":"12","key":"2019111907535828700_B23","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1007\/s00277-011-1224-1","article-title":"Effect of thalidomide with melphalan and prednisone on health-related quality of life (HRQoL) in elderly patients with newly diagnosed multiple myeloma: a prospective analysis in a randomized trial.","volume":"90","author":"Verelst","year":"2011","journal-title":"Ann Hematol"},{"issue":"19","key":"2019111907535828700_B24","doi-asserted-by":"crossref","first-page":"3160","DOI":"10.1200\/JCO.2009.26.1610","article-title":"Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study.","volume":"28","author":"Wijermans","year":"2010","journal-title":"J Clin Oncol"},{"issue":"19","key":"2019111907535828700_B25","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1056\/NEJMoa1114138","article-title":"Lenalidomide maintenance after stem-cell transplantation for multiple myeloma.","volume":"366","author":"Attal","year":"2012","journal-title":"N Engl J Med"},{"issue":"19","key":"2019111907535828700_B26","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1056\/NEJMoa1112704","article-title":"Continuous lenalidomide treatment for newly diagnosed multiple myeloma.","volume":"366","author":"Palumbo","year":"2012","journal-title":"N Engl J Med"},{"issue":"19","key":"2019111907535828700_B27","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1056\/NEJMoa1114083","article-title":"Lenalidomide after stem-cell transplantation for multiple myeloma.","volume":"366","author":"McCarthy","year":"2012","journal-title":"N Engl J Med"},{"issue":"12","key":"2019111907535828700_B28","doi-asserted-by":"crossref","first-page":"3205","DOI":"10.1182\/blood-2011-06-297853","article-title":"Approach to the treatment of multiple myeloma: a clash of philosophies.","volume":"118","author":"Rajkumar","year":"2011","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/121\/9\/1517\/1368678\/zh800913001517.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/121\/9\/1517\/1368678\/zh800913001517.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,19]],"date-time":"2019-11-19T07:54:10Z","timestamp":1574150050000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/121\/9\/1517\/138820\/A-randomized-phase-3-trial-of-thalidomide-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2,28]]},"references-count":28,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2013,2,28]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2012-09-451872","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,2,28]]}}}